Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in pretreated advanced HCC
NCT02989922Phase 2Completed
- Sponsor
- Hengrui
- Start
- Nov 2016
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Hengrui. Primary endpoints: Objective Response Rate and 6-month Overall Survival Rate. Started Nov 2016; status: completed.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02989922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989922.